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ND liceRisk of GuillaineBarre syndrome from fresh chicken in the
United KingdomAbstractA recent survey by the Food Standards Authority indicated that nearly two-thirds of chickens sold by major retailers in the UK are con-
taminated with the bacterium Campylobacter. From a public health and neurological perspective campylobacteriosis is of great importance. Not
only is it a frequent source of food poisoning, but one species, Campylobacter jejuni, is also known to trigger GuillaineBarre syndrome, the
most common cause of flaccid paralysis worldwide. Here we briefly review the pathogenesis of GuillaineBarre syndrome and highlight clinical
features of the disease.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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that nearly two-thirds of chickens sold by major retailers in the
UK are contaminated with the bacterium Campylobacter.1 The
survey tested 4011 samples of whole, UK-produced fresh
chicken between February 2014 and February 2015. Skin
contamination ranged between 66% and 80% among retailers.
Worryingly, Campylobacter was also isolated from approx-
imately 7% of exterior packaging. From a public health and
neurological perspective campylobacteriosis is of great
importance. Not only is it a frequent source of food poisoning,
but one species, Campylobacter jejuni, is also known to trigger
GuillaineBarre syndrome (GBS), the most common cause of
flaccid paralysis worldwide.2
Campylobacter is a spiral-shaped Gram-negative bacterium
and a leading cause of zoonotic disease worldwide. Most
infections in humans are caused by C. jejuni, which is carried
as a commensal organism in the gastrointestinal tracts of
poultry.3 C. jejuni is the most common cause of infectious
diarrhea in developed countries and likely to account for many
of the estimated 280,000 cases of food poisoning caused by
Campylobacter species in the UK each year.1 The symptoms
and severity of Campylobacter enteritis vary considerably.
Typically, onset of gastrointestinal symptoms and fever are
3e5 days after exposure. In some patients diarrhea is minimalx.doi.org/10.1016/j.jacme.2016.09.002
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nse (http://creativecommons.org/licenses/by-nc-nd/4.0/).and infection may be subclinical in up to half. Although C.
jejuni can be cultured from stool samples up to 2 weeks after
exposure, neurological symptoms may develop later, in which
case serological testing is advised if confirmation is required.
This is especially important if there is clustering of cases, as
this may have important public health implications. Only 1 in
1000 infected patients goes on to develop GBS.4 The exact
reasons behind this remain unclear, and although some strains
of C. jejuni are known to trigger GBS more than others,5 host
factors, including altered immune regulation are likely to be
important. In a large epidemiological study, median onset of
neurological symptoms attributable to GBS following expo-
sure to C. jejuni was 10 days and the shortest interval was 3
days.6
Clinical history, including details related to meals eaten at
communal functions and contact with others who have similar
symptoms, are important for public health purposes.
The incidence of GBS in Western countries is approx-
imately 1.11/100,000 person-years and increases with age.7
GBS represents a spectrum of related disorders which vary
considerably with respect to clinical phenotype and severity.8
In its commonest and most severe form, patients present with
ascending limb weakness associated with glove-and-stocking
type sensory disturbance. Approximately 25% of theseby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-
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mechanical ventilation. Miller Fisher syndrome is significantly
less common and associated with external ophthalmoplegia
and cerebellar-like ataxia. Other rarer subtypes also exist and
some patients may only develop ptosis.
GBS and Miller Fisher syndrome are considered post-
infectious neuropathies. C. jejuni is an important trigger and
has been isolated in up to one-third of cases. Much of what is
known about the pathogenesis of GBS has come from studying
C. jejuni. By a process of mistaken identity, known as
molecular mimicry, cross-reactivity between surface epitopes
of the bacterium C. jejuni and nerve gangliosides (GM1,
GD1a, and GQ1b) can induce pathogenic autoantibodies,
which may cause axonal-type neuropathy in some patients.2,9
Different antiganglioside antibody profiles are thought to
account for phenotypic differences between patients. For
example, ganglioside GQ1b has been identified in cranial
nerves III, IV, and VI and may explain why patients with
Miller Fisher syndrome, which is associated primarily with
anti-GQ1b antibodies, develop ophthalmoplegia.10
GBS is an important neurological emergency and up to 5%
of patients die despite modern treatment. Timely diagnosis and
commencement of appropriate treatment therefore remains
essential. Intravenous immunoglobulin and plasma exchange
are of proven benefit and improve outcome, especially if
commenced early. Diagnosis of GBS and related disorders can
be made based on clinical information alone in the majority of
patients.8 The presence of core clinical features, including
history of antecedent infection, distal paraesthesias at or
before onset, symmetric limb or cranial nerve weakness,
monophasic disease course, and diminished deep tendon
reflexes are highly suggestive of GBS and common to all
subtypes. Although cerebrospinal fluid albuminocytological
dissociation (raised protein and normal cell count) or neuro-
physiological evidence of neuropathy support diagnosis, they
may be normal or nondiagnostic early in the disease course.
Demonstration of serum antiganglioside antibodies also sup-
ports diagnosis but should not be relied upon or delay
treatment.
News that Campylobacter appears to be rife among fresh
chicken bought in the UK should also alert physicians to be
more vigilant of GBS. Knowledge of the core clinical features
of GBS and related disorders is likely to lead to early recog-
nition and treatment of this potentially life-threatening disease.
Prevention is better than cure and consumers should also be
encouraged to cook their chickens appropriately.Conflicts of interest
The authors declare no conflicts of interest.
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